Specialization
Fabry disease
Focus of research
Treatment of patients with Fabry disease with agalsidase alfa and agalsidase beta: phenotypic diversity necessitates the development of individualized treatment guidelines.
-
Adaptive pathway development for Fabry disease: a clinical approach
Schuller, Y., Arends, M., Körver, S., Langeveld, M. & Hollak, C. E. M., 2018, In: Drug Discovery Today. 23, 6, p. 1251-1257Research output: Contribution to journal › Article › Academic › peer-review
-
Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study
Arends, M., Biegstraaten, M., Wanner, C., Sirrs, S., Mehta, A., Elliott, P. M., Oder, D., Watkinson, O. T., Bichet, D. G., Khan, A., Iwanochko, M., Vaz, F. M., van Kuilenburg, A. B. P., West, M. L., Hughes, D. A. & Hollak, C. E. M., 2018, In: Journal of medical genetics. 55, p. 351-358Research output: Contribution to journal › Article › Academic › peer-review
-
Phenotype, disease severity and pain are major determinants of quality of life in Fabry disease: results from a large multicenter cohort study
Arends, M., Körver, S., Hughes, D. A., Mehta, A., Hollak, C. E. M. & Biegstraaten, M., 2018, In: Journal of inherited metabolic disease. 41, 1, p. 141-149Research output: Contribution to journal › Article › Academic › peer-review
- All publications